OMO-103 for advanced or metastatic pancreatic ductal adenocarcinoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an early Phase 1 study of OMO-103, a Myc inhibitor given by IV on days 1 and 8 of each cycle, aimed at measuring its effects on pancreatic tumor biology. Participants will have pre- and post-treatment tumor biopsies, regular blood draws, and CT or MRI imaging to track changes. The study will collect safety data and look for biomarkers that predict which tumors respond. Patients are followed 30 days after treatment and then for one year to monitor outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Must provide written informed consent before any study-specific procedures or interventions are performed
* Must be ≥ 18 years old at the time of informed consent
* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
* Clinically-confirmed diagnosis of locally-advanced or metastatic adenocarcinoma of the pancreas

  * Participants may be treatment naïve or have received prior therapy for the treatment of their PDAC. A minimum washout period of 14-days after completing the most recent line of therapy is required before a participant can initiate treatment with study agent(s)
* Based on available imaging, participant must have at least one disease lesion that can be biopsied in accordance with institutional standards
* Patient agrees to undergo a minimum of 2 biopsies (pre- and post-treatment). Note: at principal investigator (PI) discretion, archival sample may be obtained in lieu of pre-treatment biopsy
* Hemoglobin ≥ 7.5 g/dL
* Absolute neutrophil count (ANC) ≥ 1.0 x 10\^9/L (\> 1500 per mm\^3)
* Platelet count ≥ 75 x 10\^9/L (\> 100,000 per mm\^3)
* Calculated creatinine clearance \> 50 mL/min/1.73m\^2 (per Cockcroft-Gault equation)
* Aspartate aminotransferase (AST)/alanine aminotransferase (ALT): ≤ 3 x upper limit of normal (ULN), or ≤ 5 x ULN in presence of liver metastases
* Participants of childbearing potential (POCBP) must agree to abstain from sexual intercourse or use effective methods of contraception starting with the first dose of study therapy through 6 months from the last dose of study intervention
* POCBP may participate provided they have a negative serum pregnancy test at screening and a negative serum OR urine pregnancy test within 7 days of starting treatment
* Sperm-producing participants must agree to abstain from sexual intercourse or use effective contraception starting with the first dose through 6 months after last dose of study intervention

Exclusion Criteria:

* Concomitant use of other anti-cancer therapy otherwise not permitted in this protocol, including: chemotherapy, immunotherapy, hormonal therapy (hormone replacement therapy is acceptable), radiotherapy (except for palliative), biological therapy, or other novel agent
* Prior anti-cancer therapy within 2 weeks prior to study enrollment
* Prior treatment with a MYC inhibitor
* Known severe hypersensitivity to OMO-103 or to any excipient of these medicinal products, or history of allergic reactions attributed to compounds of similar chemical or biologic composition
* Major surgery within 6 weeks prior to enrollment
* Uncontrolled intercurrent illness including symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, and myocardial infarction within 3 months of initiating study intervention
* History of psychiatric illness likely to interfere with ability to comply with protocol requirements or give informed consent
* Participant is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 6 months after the last dose of trial treatment
* Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements

Where it's running

• OHSU Knight Cancer Institute
  Portland, Oregon, United States Recruiting

Study contacts

• Principal investigator: Charles D Lopez — OHSU Knight Cancer Institute

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Targeted therapy for pancreatic cancer using new drugs

  This study is testing new targeted therapies for pancreatic cancer to see how well they work and if they are safe for patients at different stages of the disease.

  Recruiting Early Phase 1 OHSU Knight Cancer Institute · Portland, Oregon · NCT04005690

• Combo therapy with selumetinib and trastuzumab deruxtecan for advanced pancreatic cancer

  This phase 1/2 trial tests whether the combination of selumetinib and DS-8201a (trastuzumab deruxtecan) is safe and whether it can help people with unresectable or metastatic pancreatic ductal adenocarcinoma.

  Recruiting Phase 1/2 National Cancer Institute (NCI) · Pittsburgh, Pennsylvania · NCT07619521

• AB801 with chemotherapy and immunotherapy for cholangiocarcinoma and pancreatic cancer

  This phase 1 study tests whether AB801 can be given safely with chemotherapy and immunotherapy in adults with border-line resectable, locally advanced, or metastatic cholangiocarcinoma or pancreatic cancer.

  Recruiting Phase 1 Jonsson Comprehensive Cancer Center · Los Angeles, California · NCT07619313

• Higher-dose targeted radiation for locally advanced pancreatic cancer

  This tests whether giving a higher, precisely targeted dose of radiation after initial chemotherapy helps people with locally advanced unresectable pancreatic cancer live longer.

  Recruiting at 327 sites Phase 3 NRG Oncology · Gilbert, Arizona and 332 other locations · NCT06958328

• Using pemigatinib to treat advanced pancreatic cancer with FGFR genetic changes

  This study is testing if a new drug called pemigatinib can help adults with advanced pancreatic cancer that has specific genetic changes feel better and possibly live longer.

  Recruiting at 109 sites Phase 2 Ohio State University Comprehensive Cancer Center · Birmingham, Alabama and 108 other locations · NCT06906562

• CPI-613 combined with hydroxychloroquine and chemotherapy for advanced solid tumors

  This study is testing a new combination of treatments, including CPI-613 and hydroxychloroquine, to see if it can help people with advanced solid tumors that haven't improved with other chemotherapy.

  Recruiting Phase 2 Northwestern University · Chicago, Illinois · NCT05733000

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.